Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

Stephen A. Harrison, Lorenzo Rossaro, Ke‐Qin Hu, Keyur Patel, Hans Tillmann, Sandeep Dhaliwal, Dawn M. Torres, Kenneth Koury, Venkata S. Goteti, Stephanie Noviello, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Mark S. Sulkowski – 26 August 2010 – Elevated low‐density lipoprotein (LDL) levels and statin use have been associated with higher sustained virological response (SVR) rates in patients receiving chronic hepatitis C therapy. However, these relationships have not been well characterized in randomized controlled trials.

HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 μg/L are at low risk of hemochromatosis

Katrina J. Allen, Nadine A. Bertalli, Nicholas J. Osborne, Clare C. Constantine, Martin B. Delatycki, Amy E. Nisselle, Amanda J. Nicoll, Dorota M. Gertig, Christine E. McLaren, Graham G. Giles, John L. Hopper, Gregory J. Anderson, John K. Olynyk, Lawrie W. Powell, Lyle C.

Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options

Maureen M. Jonas, Joan M. Block, Barbara A. Haber, Saul J. Karpen, W. Thomas London, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Kathleen B. Schwarz, Brian J. McMahon – 25 August 2010 – Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing of treatment, and the choice of antiviral therapy are complex and are compounded by the limited number of drugs that have been studied in children.

A protective role for CD154 in hepatic steatosis in mice

Julien Villeneuve, Sébastien Lepreux, Audrey Mulot, Annie M. Bérard, Arisa Higa‐Nishiyama, Pierre Costet, Victor De Ledinghen, Paulette Bioulac‐Sage, Charles Balabaud, Alan T. Nurden, Jean Rosenbaum, Eric Chevet, Jean Ripoche – 25 August 2010 – Inflammation and lipid metabolism pathways are linked, and deregulation of this interface may be critical in hepatic steatosis. The importance of the dialog between inflammatory signaling pathways and the unfolded protein response (UPR) in metabolism has been underlined.

The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus‐specific CD8+ T‐cell function

Bijan Raziorrouh, Winfried Schraut, Tilman Gerlach, Daniela Nowack, Norbert H. Grüner, Axel Ulsenheimer, Reinhart Zachoval, Martin Wächtler, Michael Spannagl, Jürgen Haas, Helmut M. Diepolder, Maria‐Christina Jung – 25 August 2010 – Multiple inhibitory receptors may play a role in the weak or absent CD8+ T‐cell response in chronic hepatitis B virus (HBV) infection. Yet few receptors have been characterized in detail and little is known about their complex regulation.

Nuclear factor κB up‐regulation of CCAAT/enhancer‐binding protein β mediates hepatocyte resistance to tumor necrosis factor α toxicity

Yongjun Wang, Rajat Singh, Youqing Xiang, Linda E. Greenbaum, Mark J. Czaja – 20 August 2010 – The sensitization of hepatocytes to cell death from tumor necrosis factor α (TNFα) underlies many forms of hepatic injury, including that from toxins. Critical for hepatocyte resistance to TNFα toxicity is activation of nuclear factor κB (NF‐κB) signaling, which prevents TNFα‐induced death by the up‐regulation of protective proteins.

miR‐194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice

Zhipeng Meng, Xianghui Fu, Xiaosong Chen, Samuel Zeng, Yan Tian, Richard Jove, Rongzhen Xu, Wendong Huang – 20 August 2010 – MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by interacting with the 3′ untranslated region (3′‐UTR) of multiple mRNAs. Recent studies have linked miRNAs to the development of cancer metastasis. In this study, we show that miR‐194 is specifically expressed in the human gastrointestinal tract and kidney.

Subscribe to